$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420416117695 Filed on August 09, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q4
Revenue	$2.412M	$2.222M	$1.761M
YoY Change	79.49%	130.55%	101.56%
Cost Of Revenue	$963.9K	$873.3K	$800.0K
YoY Change	50.88%	87.63%	142.42%
Gross Profit	$1.448M	$1.349M	$957.2K
YoY Change	105.43%	170.62%	75.84%
Gross Profit Margin	60.03%	60.71%	54.35%
Selling, General & Admin	$2.141M	$2.625M	$2.370M
YoY Change	25.91%	61.41%	-4.44%
% of Gross Profit	147.85%	194.59%	247.6%
Research & Development	$1.172M	$1.092M	$1.250M
YoY Change	35.3%	36.23%	28.87%
% of Gross Profit	80.96%	80.95%	130.59%
Depreciation & Amortization	$40.00K	$40.00K	$30.00K
YoY Change	0.0%	100.0%
% of Gross Profit	2.76%	2.97%	3.13%
Operating Expenses	$3.592M	$4.036M	$3.620M
YoY Change	25.81%	48.07%	4.93%
Operating Profit	-$2.144M	-$2.687M	-$2.214M
YoY Change	-0.28%	20.65%	-23.43%
Interest Expense	-$117.4K	$1.582K	$340.0K
YoY Change	-3778.75%	-47.94%	-113.71%
% of Operating Profit
Other Income/Expense, Net	-$43.91K	-$317.9K
YoY Change	-93.7%	-108.68%
Pretax Income	-$2.188M	-$3.005M	-$2.330M
YoY Change	-23.15%	-309.52%	-56.69%
Income Tax	$0.00	$0.00	-$320.0K
% Of Pretax Income
Net Earnings	-$2.188M	-$3.005M	-$2.000M
YoY Change	-23.15%	-309.52%	-59.92%
Net Earnings / Revenue	-90.73%	-135.23%	-113.57%
Basic Earnings Per Share		-$0.12	-$0.08
Diluted Earnings Per Share	-$86.08K	-$0.12	-$0.08
COMMON SHARES
Basic Shares Outstanding	25.44M shares	25.42M shares	25.37M shares
Diluted Shares Outstanding		25.42M shares

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.400M	$8.900M	$7.500M
YoY Change	-31.18%	-20.54%	36.36%
Cash & Equivalents	$6.375M	$8.670M	$5.317M
Short-Term Investments	$0.00	$200.0K	$2.200M
Other Short-Term Assets	$200.0K	$200.0K	$500.0K
YoY Change	-50.0%	-33.33%	-28.57%
Inventory	$1.100M	$1.000M	$1.191M
Prepaid Expenses
Receivables	$1.400M	$900.0K	$648.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.100M	$11.10M	$9.860M
YoY Change	-21.55%	-14.88%	29.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$600.0K	$600.0K	$557.3K
YoY Change	20.0%	48.95%	126.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.200M	$1.000M	$836.7K
YoY Change	71.43%	52.63%	35.88%
Total Long-Term Assets	$1.800M	$1.611M	$1.394M
YoY Change	50.0%	52.28%	61.79%
TOTAL ASSETS
Total Short-Term Assets	$9.100M	$11.10M	$9.860M
Total Long-Term Assets	$1.800M	$1.611M	$1.394M
Total Assets	$10.90M	$12.71M	$11.25M
YoY Change	-14.84%	-9.84%	32.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$1.022M	$684.6K
YoY Change	40.0%	144.55%	-1.96%
Accrued Expenses	$1.500M	$1.100M	$700.0K
YoY Change	87.5%	57.14%	-12.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$416.7K		$0.00
YoY Change
Total Short-Term Liabilities	$5.000M	$3.933M	$3.044M
YoY Change	47.06%	55.59%	-32.44%
LONG-TERM LIABILITIES
Long-Term Debt	$4.480M	$4.881M	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$4.480M	$4.881M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.000M	$3.933M	$3.044M
Total Long-Term Liabilities	$4.480M	$4.881M	$0.00
Total Liabilities	$9.479M	$8.814M	$3.044M
YoY Change	178.8%	252.57%	-32.36%
SHAREHOLDERS EQUITY
Retained Earnings		-$137.4M	-$132.5M
YoY Change			6.54%
Common Stock		$25.44K	$25.40K
YoY Change			8.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.400M	$3.897M	$9.847M
YoY Change
Total Liabilities & Shareholders Equity	$10.90M	$12.71M	$11.25M
YoY Change	-14.84%	-9.85%	32.89%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q4
OPERATING ACTIVITIES
Net Income	-$2.188M	-$3.005M	-$2.000M
YoY Change	-23.15%	-309.52%	-59.92%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$30.00K
YoY Change	0.0%	100.0%
Cash From Operating Activities	-$2.470M	-$1.920M	-$2.230M
YoY Change	9.29%	-26.15%	6.7%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	-$200.0K	-$220.0K
YoY Change	5.56%	100.0%	15.79%
Acquisitions
YoY Change
Other Investing Activities	$250.0K	$2.240M	-$250.0K
YoY Change	-79.84%	-996.0%	-104.62%
Cash From Investing Activities	$60.00K	$2.030M	-$470.0K
YoY Change	-94.34%	-680.0%	-109.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	100.0K	4.880M	600.0K
YoY Change	-82.14%	938.3%	233.33%
NET CHANGE
Cash From Operating Activities	-2.470M	-1.920M	-2.230M
Cash From Investing Activities	60.00K	2.030M	-470.0K
Cash From Financing Activities	100.0K	4.880M	600.0K
Net Change In Cash	-2.310M	4.990M	-2.100M
YoY Change	260.94%	-301.21%	-163.44%
FREE CASH FLOW
Cash From Operating Activities	-$2.470M	-$1.920M	-$2.230M
Capital Expenditures	-$190.0K	-$200.0K	-$220.0K
Free Cash Flow	-$2.280M	-$1.720M	-$2.010M
YoY Change	9.62%	-31.2%	5.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1636128	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Assets Assets	12711124	USD
CY2015Q4	us-gaap	Assets Assets	11254366	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1021535	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	684633	USD
CY2016Q2	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	1103288	USD
CY2015Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	723018	USD
CY2016Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1808347	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3933170	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3043779	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	25438	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	25397	USD
CY2016Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140755208	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140126731	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	483544	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	584317	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137367403	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-132525858	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	3896787	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	8210587	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12711124	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11254366	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	474709	USD
	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	3750	USD
	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	25000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69423	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44428	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	172219	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	102651	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-284969	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	599768	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	146428	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	292517	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-284278	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-149347	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	496208	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-352594	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-416932	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1019	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7134	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	710819	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-360356	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-833	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	98330	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	192554	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	212409	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	45402	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1943000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	2442547	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	3686000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1632261	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1481409	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3750	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	249335	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	25000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	818250	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4909917	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10476169	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-5077	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-23670	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	USD
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	9408584	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3183562	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4559026	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3353539	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-100773	USD
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	28880	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	225000	USD
CY2016Q2	ctso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue	2437000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4412064	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3605280	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8017344	USD
CY2016Q2	ctso	Number Of Patents Issued NumberOfPatentsIssued	32	pure
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	102651	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-386603	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	6556	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3275	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	382099	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	731956	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	758562	USD
CY2016Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	53838	USD
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	50020	USD
	ctso	License Period LicensePeriod	P18Y
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	736000	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	736000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.81
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.728	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0067	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y8M12D
CY2016Q2	us-gaap	Share Price SharePrice	4.55
CY2015Q2	us-gaap	Share Price SharePrice	6.8
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y8M12D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0123	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.413	pure
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	816000	shares
CY2014Q1	ctso	Fair Value Warrant Liability FairValueWarrantLiability	862920	USD
CY2014Q1	us-gaap	Share Price SharePrice	6.00
CY2016Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	190513	USD
CY2015Q3	ctso	Aggregate Registered Amount For Offerings AggregateRegisteredAmountForOfferings	100000000	USD
CY2016Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.02
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.04
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	5673	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	31.25
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.88
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1031219	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	500150	shares
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P9Y10M24D
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P8Y9M18D
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P4Y4M24D
	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm	P0Y
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	794708	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	499650	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	165410	shares
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1160867	shares
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	3.3
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.23
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0181	pure
CY2016Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	513000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	566000	shares
CY2015Q2	ctso	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedInPeriodFairValue	1388000	USD
	us-gaap	Freight Costs FreightCosts	71000	USD
	us-gaap	Freight Costs FreightCosts	67000	USD
	us-gaap	Advertising Expense AdvertisingExpense	125000	USD
	us-gaap	Advertising Expense AdvertisingExpense	117000	USD
CY2016Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4881167	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of Estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, and valuation methods used to determine the fair value of the warrant liability.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Concentration of Credit Risk</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of June 30, 2016, two distributors and one government agency accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43</font>% of outstanding grant and accounts receivable. At December 31, 2015, three distributors accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48</font>% of outstanding grant and accounts receivable. For the six months ended June 30, 2016, one direct customer accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font></font>% of the Company’s total revenue. No other agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue. For the six months ended June 30, 2015, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% of revenues were from one U.S. government grant agency. No other agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue. For the three months ended June 30, 2016, one direct customer accounted for approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 13</font>% of the Company’s total revenue. No other agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue. For the three months ended June 30, 2015, no agency, distributor, or direct customer represented more than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>% of the Company’s revenue.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2	us-gaap	Liabilities Liabilities	8814337	USD
CY2015Q4	us-gaap	Liabilities Liabilities	3043779	USD
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25437766	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25437766	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25397056	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25397056	shares
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3450119	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1476770	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1852670	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	773112	USD
	us-gaap	Revenue From Grants RevenueFromGrants	582401	USD
	us-gaap	Revenue From Grants RevenueFromGrants	198240	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	369668	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	179657	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	12003	USD
CY2016Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2015Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	11170	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	4032520	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1687013	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2222338	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	963939	USD
	us-gaap	Gross Profit GrossProfit	2339755	USD
	us-gaap	Gross Profit GrossProfit	917101	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	1349072	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	498508	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1692765	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	769912	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	873266	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	465431	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1948192	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1752684	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1092070	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	801656	USD
	us-gaap	Professional Fees ProfessionalFees	573735	USD
	us-gaap	Professional Fees ProfessionalFees	513431	USD
CY2016Q2	us-gaap	Professional Fees ProfessionalFees	319184	USD
CY2015Q2	us-gaap	Professional Fees ProfessionalFees	297913	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4595293	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3141565	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2625189	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1626398	USD
	us-gaap	Operating Expenses OperatingExpenses	7117220	USD
	us-gaap	Operating Expenses OperatingExpenses	5407680	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	4036443	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	2725967	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4777465	USD
CY2015Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	61906	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1588906	USD
CY2015Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3596832	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4490579	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2687371	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2227459	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5488	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5652	USD
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1582	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3039	USD
CY2016Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-128941	USD
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25408599	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24582590	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4942318	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3014806	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2860520	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1357957	USD
	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5000000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	118833	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-64080	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1207955	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-317872	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3661777	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4841545	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3282624	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-3005243	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1434318	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25416077	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24768639	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25408599	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24582590	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25416077	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28826158	shares
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	267818	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	144723	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-76361	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5000000	USD
CY2016Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	118833	USD
CY2016Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	241000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	241000	USD
CY2016Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	262117	USD
CY2016Q2	us-gaap	Advertising Expense AdvertisingExpense	45000	USD
CY2015Q2	us-gaap	Advertising Expense AdvertisingExpense	66000	USD
CY2016Q2	us-gaap	Freight Costs FreightCosts	37000	USD
CY2015Q2	us-gaap	Freight Costs FreightCosts	26000	USD
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	900100	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	125059	USD
CY2016Q2	ctso	Number Of Countries In Which Product Marketed NumberOfCountriesInWhichProductMarketed	37	pure
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1666667	USD
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1666667	USD
CY2016Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1666666	USD
CY2016Q2	us-gaap	Long Term Debt LongTermDebt	5000000	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2477279	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.56
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3000675	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.62
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1100166	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P9M4D
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	72400	shares
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	CTSO
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25437766	shares
	us-gaap	Interest Paid InterestPaid	1139	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	0	USD
	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	903916	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="TEXT-ALIGN: justify; WIDTH: 0.25in"> <div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: justify; WIDTH: 0.25in"> <div><font style="FONT-SIZE: 10pt"><b>1.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><b>BASIS OF PRESENTATION</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December  31, 2015 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 9, 2016. The results for the three and six months ended June 30, 2016 and 2015 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of June 30, 2016, the Company had an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">137,367,403</font>, which included net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,841,545</font> for the six months ended June 30, 2016 and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,282,624</font> for the six months ended June 30, 2015. The Company’s losses have resulted principally from costs incurred in the research and development of the Company’s polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability is uncertain. The Company’s ability to achieve profitability will depend, among other things, on successfully completing the development of the Company’s technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE Mark previously received and for potential label extensions of the Company’s current CE Mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance the Company’s activities. No assurance can be given that the Company’s product development efforts will be successful, that the Company’s current CE Mark will enable the Company to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company’s products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3005243	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	1434318	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4841545	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3282624	USD

Files In Submission

Name	View Source	Status
0001144204-16-117695-index-headers.html	Edgar Link	pending
0001144204-16-117695-index.html	Edgar Link	pending
0001144204-16-117695.txt	Edgar Link	pending
0001144204-16-117695-xbrl.zip	Edgar Link	pending
ctso-20160630.xml	Edgar Link	completed
ctso-20160630.xsd	Edgar Link	pending
ctso-20160630_cal.xml	Edgar Link	unprocessable
ctso-20160630_def.xml	Edgar Link	unprocessable
ctso-20160630_lab.xml	Edgar Link	unprocessable
ctso-20160630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tex10-3pg5.jpg	Edgar Link	pending
tex10-3pg6.jpg	Edgar Link	pending
tex10-3pg7.jpg	Edgar Link	pending
tex10-3pg8.jpg	Edgar Link	pending
tex10-3pg9.jpg	Edgar Link	pending
v445334_10q.htm	Edgar Link	pending
v445334_ex10-3.htm	Edgar Link	pending
v445334_ex31-1.htm	Edgar Link	pending
v445334_ex31-2.htm	Edgar Link	pending
v445334_ex32-1.htm	Edgar Link	pending
v445334_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2016 Q3 Form 10-Q Financial Statement

#000114420416117695 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2016 Q3 Form 10-Q Financial Statement

#000114420416117695 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso